Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of LQ036 in Healthy Subjects and Mild Asthma
NCT04993443Phase 1Terminated
- Sponsor
- Syneos Health
- Start
- Sep 2021
- Primary completion
- Mar 2023
- Modality
- Antibody Conjugates, Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in asthma comparing LQ036 with Placebo (2 arms). Primary endpoints: Safety and Tolerability of single and multiple doses up to 1 Month, Change in QTC parameters up to 1 Month and 3 more. Started Sep 2021; status: terminated.
02
Drugs
LQ036
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04993443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04993443.